Celltrion gets approval of Omlyclo in Canada

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma and chronic idiopathic urticaria treatment Xolair, the company said on Monday. 

With this approval, Celltrion can sell Omlyclo in Canada for allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic Idiopathic urticaria.

Xolair is a monoclonal antibody biopharmaceutical developed by the US-based Genentech and Novartis in Switzerland. 

Last year, Xolair reported global sales of around $3.5 billion. The Canadian market is estimated to be worth $138 million. 

Write to Jeong Min Nam at peux@hankyung.com